Pinnacle Wealth Management LLC Acquires Shares of 14,946 Hims & Hers Health, Inc. $HIMS

Pinnacle Wealth Management LLC bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,946 shares of the company’s stock, valued at approximately $442,000.

Other institutional investors have also recently made changes to their positions in the company. UMB Bank n.a. lifted its position in shares of Hims & Hers Health by 247.5% during the first quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock worth $39,000 after acquiring an additional 933 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after acquiring an additional 458 shares in the last quarter. Tsfg LLC purchased a new stake in shares of Hims & Hers Health during the first quarter worth $46,000. Fifth Third Bancorp lifted its position in shares of Hims & Hers Health by 165.4% during the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company’s stock worth $46,000 after acquiring an additional 961 shares in the last quarter. Finally, N.E.W. Advisory Services LLC purchased a new stake in shares of Hims & Hers Health during the first quarter worth $49,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on HIMS. Piper Sandler restated a “neutral” rating and set a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Bank of America increased their target price on Hims & Hers Health from $22.00 to $26.00 and gave the stock an “underperform” rating in a research report on Tuesday, April 29th. Morgan Stanley reiterated an “equal weight” rating and issued a $40.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Finally, UBS Group set a $30.00 price objective on Hims & Hers Health in a research report on Monday, June 23rd. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and an average target price of $39.83.

Hims & Hers Health Trading Down 2.2%

Shares of HIMS stock opened at $46.09 on Monday. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98. The company has a market capitalization of $10.42 billion, a PE ratio of 57.61, a price-to-earnings-growth ratio of 2.91 and a beta of 2.08. The business’s fifty day moving average is $52.96 and its 200 day moving average is $45.72.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm’s revenue was up 72.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.06 EPS. On average, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 60,000 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total value of $3,214,800.00. Following the transaction, the insider owned 169,940 shares of the company’s stock, valued at $9,105,385.20. This represents a 26.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Dudum sold 660,000 shares of the stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $50.58, for a total value of $33,382,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,214,769 shares in the company, valued at approximately $112,023,016.02. This represents a 22.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,273,034 shares of company stock worth $66,425,573 in the last three months. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.